A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

NCT04993768 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG: TPN-101, 100 mg/day
DRUG: TPN-101, 200 mg/day
DRUG: TPN-101, 400 mg/day
DRUG: Placebo

Sponsor

Transposon Therapeutics, Inc.